

Adult Congenital Heart Association

Webinars Presents:


What's New in Anticoagulation in Adult Congenital Heart Disease?

Wednesday, 8/9/2017, 8 p.m. – 9 p.m. EDT

Presenter: Karen Stout, MD

About the Webinar

Are you an adult congenital heart disease (ACHD) patient who takes warfarin (Coumadin) as a blood thinner? Do you know about the new blood thinners that are widely used in acquired cardiovascular disease? Have you ever wondered if these can be used in ACHD patients? If so, you don't want to miss this webinar. Dr. Karen Stout, ACHD Medical Director at the University of Washington and Seattle Children's Hospital, will tell you what these new medications are and whether they can be used in adults with congenital heart disease. Register today.



REGISTER NOW:

<https://zoom.us/webinar/register/11fb644c3a42a45066858a512be5123a>

About the Presenter

Dr. Stout directs the ACHD clinic at the University of Washington and Seattle Children's Hospital. She is trained in adult cardiology and then acquired additional training in congenital heart disease. She sees patients at both University of Washington and Seattle Children's Hospital. She also has expertise in echocardiography and pregnancy and heart disease. She is a member of the ACHA Medical Advisory Board. In her spare time she enjoys snowboarding, travel and other outdoor hobbies.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar is made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Gilead Sciences, Inc., and St. Jude Medical Foundation.